Tres Alchemix, an early-stage biotechnology company, has announced the closing of a $4.4 million Series A financing round on Friday, September 26, 2025. The round was led by DNX Ventures, a venture capital firm, with participation from existing investor Waseda University Ventures.
The funds from this round will be used to accelerate the development of Tres Alchemix’s predictive artificial intelligence (AI) platform and support the opening of a new laboratory at The Oxford Science Park, a hub of world-leading science and technology companies located in Oxford, UK.
Founded in 2023 by three DPhil (PhD) graduates of the University of Oxford, Tres Alchemix is focused on developing advanced technologies that combine multi-omic and multimodal big data with proprietary quantum-chemical calculation methods. This allows for the creation of predictive models of biological and biochemical processes in the human body, which can accurately forecast the behavior of new drugs. These models capture both therapeutic effects and potential side effects, enabling the design of novel small-molecule candidates that maximize efficacy while minimizing risk.
While the company’s headquarters remain in Fukuoka, Japan, Tres Alchemix established a research and development subsidiary in Oxford in 2024. With the additional funding, the company is further strengthening its regional operations and will initially focus on oncology. The team will begin designing novel hit compounds from its Oxford laboratory.
Tres Alchemix’s CEO and co-founder, Hisashi Hashimoto, expressed confidence in the potential of their technology, stating, “We believe our technology can be a game changer for the drug-discovery field. Our models can accurately predict drug effects and potential side effects and can even propose new compounds tailored to disease biology. This allows us to compress, or even bypass, the time-consuming hit-discovery phase while lowering the risk of late-stage clinical failure.”
DNX Ventures, who led the investment in Tres Alchemix, is also optimistic about the company’s potential. Akira Kurabayashi, Managing Partner and Head of Japan at DNX Ventures, stated, “We are excited to lead the investment in Tres Alchemix and their human in silico models, which simulate drug behavior in the body and enable high-precision predictions of both therapeutic effects and potential risks.”
Yoshiki Shiraishi, Partner at DNX Ventures, added, “The three co-founders, who met at the University of Oxford, bring together expertise in medicine, computer science, and quantum chemical calculations. We believe that the innovative methodology developed by these three (“Tres”) scientists will play a leading role in transforming global drug development.”
Founded in 2023 in Fukuoka, Japan, Tres Alchemix is an AI-native biotechnology company that is developing a predictive drug-design platform to create next-generation small-molecule therapies. The company’s expansion into the UK with the opening of a new laboratory at The Oxford Science Park reflects its commitment to advancing drug discovery and development through innovative technology.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.